

▼ Antibody ▲ Oligonucleotide ◆ Peptide or protein ■ Radioligand ● Small molecule

Uptick

In 2023, the US Food and Drug Administration approved 55 novel drugs, up from 37 in 2022.

DRUG NAME	ACTIVE INGREDIENT	MARKETER	INDICATION	MECHANISM OF ACTION
▲ Wainua	Eplontersen	AstraZeneca	Polyneuropathy of hereditary transthyretin-mediated amyloidosis	Transthyretin degrader
● Filsuvez	Birch triterpenes	Amryt Pharma	Dystrophic and junctional epidermolysis bullosa wounds	Unknown
● Fabhalta	Iptacopan	Novartis Pharmaceuticals	Paroxysmal nocturnal hemoglobinuria	Complement factor B inhibitor
● Ogsiveo	Nirogacestat	SpringWorks Therapeutics	Desmoid tumors	γ-Secretase inhibitor
● Truqap	Capivasertib	AstraZeneca	Breast cancer	Kinase inhibitor
◆ Ryzneuta	Efbemalenograstim	Evive Biotechnology Singapore	Neutropenia	Leukocyte growth factor
● Augtyro	Repotrectinib	Bristol Myers Squibb	Non-small-cell lung cancer	Kinase inhibitor
● Defencath	Taurolidine and heparin	CorMedix	Catheter-related bloodstream infections	Antimicrobial and coagulation factor inhibitor
● Fruzaqla	Fruquintinib	Takeda Pharmaceuticals USA	Colorectal cancer	Kinase inhibitor
▼ Loqtorzi	Toripalimab	Coherus BioSciences	Nasopharyngeal carcinoma	Programmed cell death protein receptor-1 blocker
▼ OmvoH	Mirikizumab	Eli Lilly and Company	Ulcerative colitis	Interleukin-23 receptor antagonist
● Agamree	Vamorolone	Santhera Pharmaceuticals	Duchenne muscular dystrophy	Corticosteroid
▼ Bimzelx	Bimekizumab	UCB	Plaque psoriasis	Interleukin-17A receptor and interleukin-17F receptor antagonist
◆ Zilbrysq	Zilucoplan	UCB	Myasthenia gravis	Complement C5 inhibitor
● Velsipity	Etrasimod	Pfizer	Ulcerative colitis	Sphingosine 1-phosphate receptor modulator
▲ Rivfloza	Nedosiran	Novo Nordisk	Primary hyperoxaluria type 1	RNA interference
◆ Pombiliti	Cipaglucosidase	Amicus Therapeutics	Pompe disease	Glycogen degrader
● Exxua	Gepirone	Fabre-Kramer Pharmaceuticals	Major depressive disorder	5-Hydroxytryptamine receptor 1A agonist
● Ojjaara	Momelotinib	GSK	Myelofibrosis	Kinase inhibitor
◆ Aphexda	Motixafortide	BioLineRx	Multiple myeloma	Hematopoietic stem cell mobilizer
▼ Veopoz	Pozelimab	Regeneron Pharmaceuticals	CD55-deficient protein-losing enteropathy, also known as CHAPLE disease	Terminal complement C5 inhibitor
● Sohonos	Palovarotene	Ipsen Biopharmaceuticals	Fibrodysplasia ossificans progressiva	Retinoic acid receptor agonist
▼ Elrefxio	Elranatamab	Pfizer	Multiple myeloma	Bispecific B-cell maturation antigen-directed T-cell engager
▼ Talvey	Talquetamab	Janssen Biotech	Multiple myeloma	Bispecific GPRC5D-directed CD3 T-cell engager
▲ Izervay	Avacincaptad pegol	Iveric Bio	<i>Macular degeneration</i>	Complement C5 inhibitor
● Zurzuvae	Zuranolone	Sage Therapeutics	Postpartum depression	Allosteric γ-aminobutyric acid receptor modulator
● Xdemvy	Lotilaner	Tarsus Pharmaceuticals	Demodex blepharitis	γ-Aminobutyric acid-gated chloride channel inhibitor
● Vanflyta	Quizartinib	Daiichi Sankyo	Acute myeloid leukemia	Kinase inhibitor
▼ Beyfortus	Nirsevimab	Sanofi	Respiratory syncytial virus	RSV F protein inhibitor
◆ Ngenla	Somatogon	Pfizer	Inadequate secretion of endogenous growth hormone	Growth hormone receptor binder
▼ Rystiggo	Rozanolixizumab	UCB	Generalized myasthenia gravis	Neonatal Fc receptor binder
● Litfulo	Ritlecitinib	Pfizer	Severely patchy hair loss	Janus kinase 3 inhibitor
▼ Columvi	Glofitamab	Genentech	Large B-cell lymphoma	CD20 and CD3 receptor binder
● Inpefa	Sotagliflozin	Lexicon Pharmaceuticals	Heart failure	Sodium-glucose cotransporter 2 inhibitor
■ Posluma	Flotufolastat fluorine-18	Blue Earth Diagnostics	Positron-emission tomography imaging in patients with prostate cancer	Prostate-specific membrane antigen binder
● Paxlovid	Nirmatrelvir and ritonavir	Pfizer	COVID-19	SARS-CoV-2 main protease inhibitor
● Xacduro	Sulbactam and durlobactam	Innoviva Specialty Therapeutics	Bacterial pneumonia	β-Lactamase inhibitors
▼ Epkinly	Epcoritamab	Genmab	B-cell lymphoma	CD20-directed CD3 T-cell engager
● Miebo	Perfluorhexyloctane	Bausch & Lomb	Dry eye disease	Unknown
● Veozah	Fezolinetant	Astellas Pharma	Hot flashes caused by menopause	Neurokinin 3 receptor antagonist
◆ Elfabrio	Pegunigalsidase	Chiesi Global Rare Diseases	Fabry disease	Exogenous source of α-galactosidase A
▲ Qalsody	Tofersen	Biogen	Amyotrophic lateral sclerosis	Superoxide dismutase 1 mRNA degrader
● Joenja	Leniolisib	Pharming Healthcare	Activated phosphoinositide 3-kinase δ syndrome	Kinase inhibitor
● Rezzayo	Rezafungin	Melinta Therapeutics	Candidemia and invasive candidiasis	1,3-β-D-glucan synthase inhibitor
▼ Zynyz	Retifanlimab	Incyte	Merkel cell carcinoma	Programmed cell death protein 1 blocker
● Daybue	Trofinetide	Acadia Pharmaceuticals	Rett syndrome	Unknown
● Zavzpret	Zavegepant	Pfizer	Migraine	Calcitonin gene-related peptide receptor antagonist
● Skyclarys	Omaveloxolone	Reata Pharmaceuticals	Friedreich's ataxia	Unknown
● Filspari	Sparsentan	Traverse Therapeutics	Immunoglobulin A nephropathy	Endothelin and angiotensin II receptor antagonist
◆ Lamzede	Velmanase	Chiesi Global Rare Diseases	α-Mannosidosis	Exogenous source of α-mannosidase
● Jesduvroq	Daprodustat	GSK	Anemia caused by chronic kidney disease	Hypoxia-inducible factor prolyl hydroxylase inhibitor
● Orserdu	Elacestrant	Stemline Therapeutics	Breast cancer	Estrogen receptor antagonist
● Jaypirca	Pirtobrutinib	Eli Lilly and Company	Mantle cell lymphoma	Kinase inhibitor
● Brenzavvy	Bexagliflozin	TheracosBio	Type 2 diabetes	Sodium-glucose cotransporter 2 inhibitor
▼ Leqembi	Lecanemab	Eisai	Alzheimer's disease	Amyloid-β plaque reducer

Sources: US Food and Drug Administration, companies. Note: Drugs are shown in reverse chronological order of approval during 2023.